ARDELYX is a biopharmaceutical company based in Massachusetts. Its filings show it lobbied mainly on Medicare and Medicaid rules, specifically seeking to influence the 2025 End-Stage Renal Disease (ESRD) payment rule about whether oral-only drugs are included in the ESRD bundled payment. It hired The McManus Group and reported about $200,000 across recent filings.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JOHN MCMANUS
The latest disclosures for this client.
THE MCMANUS GROUP
Q2THE MCMANUS GROUP
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE MCMANUS GROUP
ABIGAIL SMITH
THE MCMANUS GROUP
THE MCMANUS GROUP
Q4THE MCMANUS GROUP
Q3THE MCMANUS GROUP
Q2THE MCMANUS GROUP
Q1THE MCMANUS GROUP
RR